SAN DIEGO, March 1 /PRNewswire/ -- Trius Therapeutics, Inc. announced that on February 26th, 2010, the FDA issued new draft guidance on non-inferiority clinical trials that will apply to the design of the Company's proposed Phase 3 trials for its investigational antibacterial drug torezolid phosphate. Trius is conforming the protocol for its first Phase 3 clinical trial with the new draft guidance and plans to submit the revised protocol to the FDA as soon as possible. The Company believes that the draft guidance will provide greater clarity to the process of finalizing the design of its Phase 3 trials. As a result of the new guidance, the Company has temporarily delayed its IPO until it can modify the protocol for its Phase 3 trial.
This press release contains forward-looking statements regarding the timing of the Company's resubmission of its Phase 3 clinical trial protocol and the timing of the Company's initial public offering. The impact of the FDA's new draft guidance and any future legislative and policy changes on the timing, costs and design of the Phase 3 clinical program for torezolid phosphate and the Company's initial public offering is uncertain, and actual results may differ materially from those in these forward-looking statements. For a further description of these and other risks, please see the risk factors described in the Company's Registration Statement on Form S-1 that was originally filed with the United States Securities and Exchange Commission on November 6, 2009, and the amendments thereto, including those factors discussed under the caption "Risk Factors" in such filings. Forward-looking statements speak only as of the date of this release, and Trius undertakes no obligation to update or revise these statements, except as may be required by law.
About Trius Therapeutics
Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections.
Jason Spark at Porter Novelli Life Sciences
SOURCE Trius Therapeutics, Inc.